This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
5jyo
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Allosteric inhibition of Kidney Isoform of Glutaminase== | ==Allosteric inhibition of Kidney Isoform of Glutaminase== | ||
| - | <StructureSection load='5jyo' size='340' side='right' caption='[[5jyo]], [[Resolution|resolution]] 2.10Å' scene=''> | + | <StructureSection load='5jyo' size='340' side='right'caption='[[5jyo]], [[Resolution|resolution]] 2.10Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[5jyo]] is a 8 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5JYO OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5JYO FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5jyo]] is a 8 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5JYO OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5JYO FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=63J:2-(PYRIDIN-2-YL)-N-(5-{4-[6-({[3-(TRIFLUOROMETHOXY)PHENYL]ACETYL}AMINO)PYRIDAZIN-3-YL]BUTYL}-1,3,4-THIADIAZOL-2-YL)ACETAMIDE'>63J</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=63J:2-(PYRIDIN-2-YL)-N-(5-{4-[6-({[3-(TRIFLUOROMETHOXY)PHENYL]ACETYL}AMINO)PYRIDAZIN-3-YL]BUTYL}-1,3,4-THIADIAZOL-2-YL)ACETAMIDE'>63J</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5jyp|5jyp]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5jyp|5jyp]]</td></tr> | ||
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">GLS, GLS1, KIAA0838 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Glutaminase Glutaminase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.5.1.2 3.5.1.2] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Glutaminase Glutaminase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.5.1.2 3.5.1.2] </span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5jyo FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5jyo OCA], [http://pdbe.org/5jyo PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5jyo RCSB], [http://www.ebi.ac.uk/pdbsum/5jyo PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5jyo ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5jyo FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5jyo OCA], [http://pdbe.org/5jyo PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5jyo RCSB], [http://www.ebi.ac.uk/pdbsum/5jyo PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5jyo ProSAT]</span></td></tr> | ||
| Line 11: | Line 12: | ||
== Function == | == Function == | ||
[[http://www.uniprot.org/uniprot/GLSK_HUMAN GLSK_HUMAN]] Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine. Plays a role in maintaining acid-base homeostasis. Regulates the levels of the neurotransmitter glutamate in the brain. Isoform 2 lacks catalytic activity. | [[http://www.uniprot.org/uniprot/GLSK_HUMAN GLSK_HUMAN]] Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine. Plays a role in maintaining acid-base homeostasis. Regulates the levels of the neurotransmitter glutamate in the brain. Isoform 2 lacks catalytic activity. | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Cancer cells employ glutaminolysis to provide a source of intermediates for their upregulated biosynthetic needs. Glutaminase, which catalyzes the conversion of glutamine to glutamate, is gaining increasing attention as a potential drug target. Small-molecule inhibitors such as BPTES and CB-839, which target the allosteric site of glutaminase with high specificity, demonstrate immense promise as anti-tumor drugs. Here, we report the study of a new BPTES analog, N,N'-(5,5'-(trans-cyclohexane-1,3-diyl)bis(1,3,4-tiadiazole-5,2-diyl))bis(2-pheny lacetamide) (trans-CBTBP), and compared its inhibitory effect against that of CB-839 and BPTES. We show that CB-839 has a 30- and 50-fold lower IC50 than trans-CBTBP and BPTES, respectively. To explore the structural basis for the differences in their inhibitory efficacy, we solved the complex structures of cKGA with 1S, 3S-CBTBP and CB-839. We found that CB-839 produces a greater degree of interaction with cKGA than 1S, 3S-CBTBP or BPTES. The results of this study will facilitate the rational design of new KGA inhibitors to better treat glutamine-addicted cancers. | ||
| + | |||
| + | Structural basis for exploring the allosteric inhibition of human kidney type glutaminase.,Ramachandran S, Pan CQ, Zimmermann SC, Duvall B, Tsukamoto T, Low BC, Sivaraman J Oncotarget. 2016 Sep 6;7(36):57943-57954. doi: 10.18632/oncotarget.10791. PMID:27462863<ref>PMID:27462863</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 5jyo" style="background-color:#fffaf0;"></div> | ||
| + | |||
| + | ==See Also== | ||
| + | *[[Glutaminase 3D structures|Glutaminase 3D structures]] | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Glutaminase]] | [[Category: Glutaminase]] | ||
| + | [[Category: Human]] | ||
| + | [[Category: Large Structures]] | ||
[[Category: Jayaraman, S]] | [[Category: Jayaraman, S]] | ||
[[Category: Sivaraman, J]] | [[Category: Sivaraman, J]] | ||
Revision as of 12:07, 25 December 2019
Allosteric inhibition of Kidney Isoform of Glutaminase
| |||||||||||
Categories: Glutaminase | Human | Large Structures | Jayaraman, S | Sivaraman, J | Allosteric inhibition | Gac | Hydrolase | Kga | Warburg effect
